AzTrials
AzTrials

Liver MetastasesPOEMNCT07781306

PrOspEctive Metastases Imaging (POEM)

An observational study of Liver Metastases and Colorectal Cancer, run by Cancer Research Antwerp at 1 site in Belgium.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used for medical imaging, in order to correlate the histopathological growth patterns in a… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Liver Metastases, Colorectal Cancer, Breast Cancer
How many people
50 participants
Where
1 siteBelgium
Study dates
8 Sep 2020to May 2028
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with liver metastatic colorectal or breast carcinoma undergoing a surgical excision of the liver metastases

Who may be able to join

  • ≥ 18 years old.
  • Patients with liver metastatic colorectal or breast carcinoma undergoing a surgical excision of the liver metastases
  • Therapy-naive patients as well as patients with neo-adjuvant therapy are eligible for inclusion
  • Willingness of the patient to participate in this study demonstrated by signed written informed consent

Who cannot join

  • Patients without MRI or CT of the liver prior to surgery
  • Time interval between medical imaging, CT and/or MRI is more than 12 weeks (nb: time interval is preferably less than 4 weeks but this is not an exclusion criterium)
  • Prior radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) on the liver metastasis that would be operated

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Peter Vermeulen, MD, PhD contact

0032493194745

peter.vermeulen@zas.be

Emily Latacz, MD contact

0032476547112

emily.latacz@zas.be

Belgium1 site, 1 recruiting
  • GZA St Augustinus

    Wilrijk, Antwerp, 2610

    Peter Vermeulen, MD, 0032493194745, peter.vermeulen@zas.be

    Emily Latacz, MD, 0032476547112, emily.latacz@zas.be

    Recruiting

Other trials in Belgium

About this study

Official title: Prospective Complete Histopathological Characterization of Liver Metastases From Colorectal and Breast Carcinoma to Predict the Histopathological Growth Patterns by Medical Imaging - PrOspEctive Metastases Imaging (POEM)

This is a non-interventional, observational study with an optional interventional biobanking activity. Liver metastases of patients undergoing partial hepatectomy will be sampled completely while respecting the orientation used for medical imaging, in order to correlate the histopathological growth patterns in a 3D-map with the imaging characteristics. The full pathological sampling will only use remnant tissue.

Read the detailed description

Colon cancer is a major cause of death among different cancer types. The tumor in the colon can often be treated with curative intent (by surgery, possibly in combination with medication (chemotherapy)). However, in the vast majority of patients who die from colon cancer, metastases are the real cause of death. This usually involves liver metastases. These metastases can be surgically removed and patients are often treated peri-operatively with chemotherapy or other medication although this treatment is not always successful. The existing method, eg a clinical risk score, that is being used to predict which patient will benefit from a specific treatment of liver metastases is inaccurate.

Over the past fifteen years, the investigators of the Translational Cancer Research Unit have conducted research that explains, at least partly, why not all liver metastases from colon cancer behave in the same way. These differences can be observed by histopathological examination. Surprisingly, liver metastases behave in two very different ways, or growth patterns, and this information is currently not being used in clinical practice. However, the biological differences in the behavior of the cancer cells between these two growth patterns are pronounced. In one growth pattern - "desmoplastic" - the cancer cells behave as in the primary colon cancer itself: they form groups and create new supportive tissue - or "desmoplasia" - and blood vessels - or "angiogenesis". Inflammation is often present in this type of metastases. In the other growth pattern - 'replacement' - the cancer cells behave in a special way: they take the place of, or 'replace', the normal cells of the liver, the hepatocytes, and use the available supporting tissue and blood vessels of the host. There is no formation of new blood vessels and there is often little or no inflammation. When more than one growth pattern is present in a liver metastasis, the relative contribution of each growth pattern is estimated (percentage).

These different growth patterns contain important information on the success of the treatment of the individual patient. A large retrospective study of 732 patients, where liver metastases from colon cancer were surgically removed, identified a group of patients (19%) with an exclusive desmoplastic growth pattern in all sections of the resected liver metastasis. This subgroup is associated with good survival and progression-free survival. In contrast, patients with any amount of replacement growth, have a significantly shorter overall survival. However, large retrospective studies have shown that these patients with a 'replacement' growth pattern have a survival advantage of adjuvant treatment, i.e. after surgery for liver metastasis, often a combination of chemotherapy and a treatment that inhibits angiogenesis (for example bevacizumab) is given. This is in contrast to patients with the "desmoplastic" growth pattern, the intrinsically more favorable pattern, where this treatment has no survival benefit and is therefore probably not necessary after surgery. These patients may be the so-called "oligometastatic" patients who may benefit from repeated local targeted therapies. The prognostic and predictive value of the growth patterns has been demonstrated not only in patients with colorectal cancer but also in patients with uveal melanoma, skin melanoma and breast carcinoma.

The concept of tumor growth patterns is innovative (and still underexposed in the scientific literature) and offers important perspectives for clinical application. Anti-angiogenic treatment as well as immunotherapy achieved poor results in clinical studies of metastatic colon cancer. The investigators are convinced that a better selection of patients based on characteristics of the liver metastasis, and not only based on characteristics of the primary colon tumor, could lead to success in clinical studies.

Thus, the growth patterns have an important clinical value and provide the treating physician with yet unknown information about the behavior of a liver metastasis in an individual patient. The limitation, of course, is that the growth pattern can only be determined after hepatic surgery. It would be much more useful to be able to identify the growth patterns by means of medical imaging, allowing the treatment to be tailored to the patient even before surgery. (for example; is there an additional benefit of starting chemotherapy prior to surgery?) Therefore, the aim of the current project is to ascertain whether the investigators can identify the growth patterns of these tumors by means of imaging with CT (computed tomography) or MRI (nuclear spin tomography). Some published studies suggest that medical imaging can capture the histopathological growth patterns, but these are all retrospective studies with a small number of patients and incomplete pathological sampling of the liver metastases. One study in 2007 correlated the early peri-lesional gadolinium enhancement of the liver metastasis with the presence of the desmoplastic reaction with vascular proliferation and inflammation. More recently, a study of Cheng and colleagues claimed that the prediction of the growth patterns would be possible with radiomics based on CT images.

By identifying the growth patterns in a non-invasive manner, by means of medical imaging, the investigators will be able to use the growth patterns in prospective clinical studies to truly test the predictive power.

This project concerns liver metastases of primary colorectal carcinoma as well as primary breast carcinoma. The research will therefore mainly, but not only, help patients with liver metastases of colorectal cancer and breast cancer when a translation of this project from the pre-clinical phase (explorative study) to the clinical phase (randomized studies with patients) is done.

Keywords
Histopathological growth pattern, Radiomics
Medical subject headings
Colorectal Neoplasms, Breast Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Radiomics Analysis Pipeline The imaging analysis has been designed to predict the continuous proportion and spatial distribution of HGPs

    Radiomics Analysis Pipeline The imaging analysis has been designed to predict the continuous proportion and spatial distribution of HGPs. CT will be the principal modality because it is routinely acquired in patients undergoing liver surgery and is more broadly available for subsequent validation. MRI will be analyzed in a complementary exploratory framework when anatomical sequences are available. Analyses will be performed at three linked spatial scales: (a) the entire metastasis and its concentric peritumoral environment; (b) localized CT patches corresponding to histologically mapped interface segments; and (c) the background liver as an organ-level biological context. Handcrafted radiomics, foundation-model embeddings and localized patch analysis will be used.

    Measured: 7 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2026
  2. Study start8 Sep 2020
  3. Primary completionDec 2027 (estimated)
  4. Study completionMay 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
50 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07781306
Sponsor's protocol ID
CTOO20084GZA
Acronym
POEM
Status last verified
Aug 2026
First submitted
15 Feb 2021
Last updated
24 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Metastases and Colorectal Cancer, run by Cancer Research Antwerp at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 24 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Peter Vermeulen, MD, PhD (0032493194745, peter.vermeulen@zas.be), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Radiomics Analysis Pipeline The imaging analysis has been designed to predict the continuous proportion and spatial distribution of HGPs (time frame: 7 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in